Key result
Anakinra fails to improve peak exercise capacity or rehospitalization in recently decompensated systolic heart failure.
Why the study?
Does IL-1 receptor antagonist (anakinra) inhibit the inflammatory response and improve peak aerobic exercise capacity in patients with recently decompensated systolic HF?
RCT
Does IL-1 receptor antagonist (anakinra) inhibit the inflammatory response and improve peak aerobic exercise capacity in patients with recently decompensated systolic HF?
p-value: p==0.10
No benefit on exercise capacity or rehospitalization; leaves open IL-1 inhibition as a target in systolic HF.
BACKGROUND: An enhanced inflammatory response predicts worse outcomes in heart failure (HF). We hypothesized that administration of IL-1 (interleukin-1) receptor antagonist (anakinra) could inhibit the inflammatory response and improve peak aerobic exercise capacity in patients with recently decompensated systolic HF. METHODS AND RESULTS: =0.10). CONCLUSIONS: and rehospitalization for HF. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01936909.
No takes yet. Share an insight, caveat, or question.
Tassell et al. (2017) conducted an RCT in recently decompensated systolic heart failure. anakinra (IL-1 receptor antagonist) was evaluated on peak aerobic exercise capacity (p==0.10). Administration of the IL-1 receptor antagonist anakinra was evaluated for improving peak aerobic exercise capacity and rehospitalization in recently decompensated systolic heart failure (P=0.10).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: